Table 3 Logistic regression analysis concerning age, gender, renal function and medications in relation to the population with HF diagnoses and the population with no diagnosis of HF and BNP > 100 ng/L
From: Prevalence and treatment of heart failure in Swedish nursing homes
Variable | HF diagnoses (n = 66) | No HF diagnoses and BNP > 100 ng/L (n = 154) | p-value | OR | CI 95% for OR |
|---|---|---|---|---|---|
Age (years) | 86.8 ± 5.6 (n = 66) | 87.0 ± 6.0 (n = 66) | 0.82 | 1.02 | 0.94-1.08 |
Male sex n (%) | 20 (30.3) | 44 (28.6) | 0.91 | 0.96 | 0.44-2.10 |
eGFR (ml/min/1.73 m2) | 35.9 ± 16.4 (n = 62) | 42.1 ± 15.4 (n = 152) | 0.27 | 0.99 | 0.96-1.01 |
ACE inhibitors/ARBs | 33 (50) | 23 (14.9) | <0.001 | 11.27 | 3.14-40.41 |
Beta-blockers | 39 (59.1) | 70 (45.5) | 0.99 | 1.00 | 0.48-2.08 |
Spironolactone | 10 (15.2) | 8 (5.2) | 0.04 | 3.55 | 1.08-11.68 |
Digoxin | 16 (24.2) | 14 (9.1) | 0.31 | 1.66 | 0.62-4.43 |
Furosemide/loop diuretics | 50 (75.8) | 50 (32.5) | <0.001 | 5.97 | 2.39-14.92 |
Loop diuretics with simultaneous ACE inhibitor/ARB treatment | 24 (36.4) | 35 (22.7) | 0.08 | 0.25 | 0.05-1.16 |